Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Cell & Gene Therapy

Stem cell research and commercialization in China...

Neurophth Closes $60 Million C Round for Ophthalmic Gene Therapies

EdiGene Forms University Collaboration for RNA Edited Genetic Therapies

IASO Starts China Phase I/II Trial of CD19/CD22 CAR-T for Lymphoma

Arbor, a US Gene Editing Company, Raises $215 Million Led by Singapore, Hong Kong, US Investors

BeiGene Pays $45 Million Upfront for Global Rights to Shoreline Cell Therapies

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China